The ETV3 antibody targets the ETS variant transcription factor 3 (ETV3), a member of the ETS family of DNA-binding proteins involved in regulating gene expression. ETV3. also known as METS or PE1. plays roles in cell differentiation, proliferation, and immune response modulation. It interacts with co-repressors like mSin3A and histone deacetylases (HDACs) to repress transcription, influencing pathways such as TGF-β signaling. Research has linked ETV3 to immune regulation, particularly in macrophages and dendritic cells, where it may suppress inflammatory responses. In cancer, ETV3 exhibits dual roles: it acts as a tumor suppressor in some contexts (e.g., breast cancer) by inhibiting oncogenic pathways, while in others (e.g., leukemia), its overexpression correlates with disease progression. Antibodies against ETV3 are critical tools for studying its expression, localization, and molecular interactions via techniques like Western blotting, immunohistochemistry, and ChIP-seq. Recent studies explore its potential as a therapeutic target or biomarker, given its involvement in epigenetic silencing and tumor microenvironment regulation. Commercial ETV3 antibodies are typically validated for specificity across human and mouse models, aiding translational research in immunology and oncology.